• Mashup Score: 0

    Jens Vogel-Claussen, MD, Hannover Medical School, Hannover, Germany, discusses final results from the German HANSE study (NCT04913155), which aimed to assess the effectiveness of two different eligibility criteria models for lung cancer screening: the Netherlands Leuvens Longkanker Screenings Onderzoek (NELSON) and PLCOm2012 models. The PLCOm2012 criteria were found to be reliable and more efficient, suggesting their preference for identifying high-risk individuals in lung cancer screening programs. Longitudinal outcome analysis is planned for further assessment. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 🎥Jens Vogel-Claussen, MD, discusses German HANSE study's promising results, favoring PLCOm2012 criteria for lung cancer screening eligibility over NELSON: ➡️https://t.co/ufu5E4hw43⬅️ #WCLC23 #LungCancer

  • Mashup Score: 0

    Marcelo Negrao, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest developments in targeting non-G12C KRAS mutations in the treatment of non-small cell lung cancer (NSCLC). This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 🎥@mvnegrao (@MDAndersonNews) iscusses the latest developments in targeting non-G12C KRAS mutations in the treatment of #NSCLC: ➡️https://t.co/ZazZV7Cmqj⬅️ #WCLC23 #LungCancer #LCSM

  • Mashup Score: 0

    Shalini Vinod, MBBS, University of New South Wales, Sydney, Australia, outlines the importance of radiotherapy in treating local regional non-small cell lung cancer (NSCLC). The treatment of lung cancer often places an emphasis on systemic therapies and surgeries, causing radiotherapy to become an understated modality. Radiotherapy is crucial in locally advanced lung cancer such as stage III NSCLC. Dr Vinod emphasises that the late presentations and stages of lung cancer result in radiotherapy playing a greater role in treatment than surgery. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 🎥@shalinivinod13 (@UNS) emphasizes the crucial role of radiotherapy in locally advanced #NSCLC treatment, often overshadowed by systemic therapies and surgeries: ➡️https://t.co/BvHonpMyzP⬅️ #WCLC23 #LCSM #RadOnc #LungCancer

  • Mashup Score: 1

    In advanced non–small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR), the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 World Lung Cancer Conference suggest this approach is of limited benefit in this subset. IMpower151, where 52% of patients had EGFR -mutant lung cancer, did not meet its primary endpoint of

    Tweet Tweets with this article
    • Checkpoint Inhibitors Offer Limited Benefit in EGFR-Mutated Lung Cancer After Disease Progression https://t.co/PWszGPF6QX #LCSM #lungcancer #oncology #immunotherapy #WCLC23

  • Mashup Score: 2

    This webinar will include a sampling of patient advocate research abstracts from presented at the 2023 IASLC World Conference on Lung Cancer (WCLC23) in Singapo …

    Tweet Tweets with this article
    • Join us for an IASLC/STARS webinar including sampling of patient advocate research abstracts presented during #WCLC23 & a live Q&A session moderated by #lungcancer patient/research advocate @JFreemanDaily: https://t.co/J8KHKBDcZ9 #LCSM @jillfeldman4 @BairdAM @ProjectBreath #LCSM https://t.co/kfuBrXpjsT